Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
Official title: A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1104
Start Date
2026-09-30
Completion Date
2029-11-30
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
MK-8748
Administered by intravitreal injection (IVT)
Aflibercept
Administered by intravitreal injection (IVT)